+
Open data
-
Basic information
Entry | ![]() | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Title | Post-fusion ectodomain of HSV-1 gB in complex with BMPC-23 Fab | |||||||||
![]() | HSV-1 gB in complex with BMPC23 Fab | |||||||||
![]() |
| |||||||||
Function / homology | ![]() host cell Golgi membrane / host cell endosome membrane / symbiont entry into host cell / ![]() ![]() Similarity search - Function | |||||||||
Biological species | ![]() ![]() ![]() ![]() ![]() ![]() | |||||||||
Method | ![]() ![]() | |||||||||
![]() | Windsor IW / Kong SL / Garforth SJ / Almo SC / Harrison SC | |||||||||
Funding support | ![]()
| |||||||||
![]() | ![]() Title: A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice. Authors: Masayuki Kuraoka / Clare Burn Aschner / Ian W Windsor / Aakash Mahant Mahant / Scott J Garforth / Susan Luozheng Kong / Jacqueline M Achkar / Steven C Almo / Garnett Kelsoe / Betsy C Herold / ![]() Abstract: There is an unmet need for monoclonal antibodies (mAbs) for prevention or as adjunctive treatment of herpes simplex virus (HSV) disease. Most vaccine and mAb efforts focus on neutralizing antibodies, ...There is an unmet need for monoclonal antibodies (mAbs) for prevention or as adjunctive treatment of herpes simplex virus (HSV) disease. Most vaccine and mAb efforts focus on neutralizing antibodies, but for HSV this strategy has proven ineffective. Preclinical studies with a candidate HSV vaccine strain, ΔgD-2, demonstrated that non-neutralizing antibodies that activate Fcγ receptors (FcγRs) to mediate antibody-dependent cellular cytotoxicity (ADCC) provide active and passive protection against HSV-1 and HSV-2. We hypothesized that this vaccine provides a tool to identify and characterize protective mAbs. We isolated HSV-specific mAbs from germinal center and memory B cells and bone marrow plasmacytes of ΔgD-2-vaccinated mice and evaluated these mAbs for binding, neutralizing, and FcγR-activating activity and for protective efficacy in mice. The most potent protective mAb, BMPC-23, was not neutralizing but activated murine FcγRIV, a biomarker of ADCC. The cryo-electron microscopic structure of the Fab-glycoprotein B (gB) assembly identified domain IV of gB as the epitope. A single dose of BMPC-23 administered 24 hours before or after viral challenge provided significant protection when configured as mouse IgG2c and protected mice expressing human FcγRIII when engineered as a human IgG1. These results highlight the importance of FcR-activating antibodies in protecting against HSV. | |||||||||
History |
|
-
Structure visualization
Supplemental images |
---|
-
Downloads & links
-EMDB archive
Map data | ![]() | 315.4 MB | ![]() | |
---|---|---|---|---|
Header (meta data) | ![]() ![]() | 16 KB 16 KB | Display Display | ![]() |
FSC (resolution estimation) | ![]() | 15.9 KB | Display | ![]() |
Images | ![]() | 59.8 KB | ||
Others | ![]() ![]() | 275.8 MB 275.8 MB | ||
Archive directory | ![]() ![]() | HTTPS FTP |
-Related structure data
Related structure data | ![]() 7uhzMC ![]() 7ui0C M: atomic model generated by this map C: citing same article ( |
---|---|
Similar structure data | Similarity search - Function & homology ![]() |
-
Links
EMDB pages | ![]() ![]() |
---|
-
Map
File | ![]() | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | HSV-1 gB in complex with BMPC23 Fab | ||||||||||||||||||||
Voxel size | X=Y=Z: 0.825 Å | ||||||||||||||||||||
Density |
| ||||||||||||||||||||
Symmetry | Space group: 1 | ||||||||||||||||||||
Details | EMDB XML:
|
-Supplemental data
-Half map: half map 2
File | emd_26520_half_map_1.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | half map 2 | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-Half map: half map 1
File | emd_26520_half_map_2.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | half map 1 | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-
Sample components
-Entire : Trimeric HSV-1 gB in complex with three BCMP-23 Fabs
Entire | Name: Trimeric HSV-1 gB in complex with three BCMP-23 Fabs |
---|---|
Components |
|
-Supramolecule #1: Trimeric HSV-1 gB in complex with three BCMP-23 Fabs
Supramolecule | Name: Trimeric HSV-1 gB in complex with three BCMP-23 Fabs / type: complex / ID: 1 / Chimera: Yes / Parent: 0 / Macromolecule list: all |
---|---|
Source (natural) | Organism: ![]() ![]() ![]() |
-Macromolecule #1: BMPC-23 Fab Heavy chain
Macromolecule | Name: BMPC-23 Fab Heavy chain / type: protein_or_peptide / ID: 1 / Number of copies: 3 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: ![]() ![]() ![]() |
Molecular weight | Theoretical: 13.425734 KDa |
Recombinant expression | Organism: ![]() ![]() |
Sequence | String: QVQLQQSGPE LVKPGASVKL SCKASGYSFT TYDINWVKER PGQGLEWIGW IYPREGSTNY NEKFRGKATL TADTSSSTAY MELHSLTSE DSAVYFCATY GSSRYYTMDY WGQGTSVTVS SA |
-Macromolecule #2: BMPC-23 Fab Light chain
Macromolecule | Name: BMPC-23 Fab Light chain / type: protein_or_peptide / ID: 2 / Number of copies: 3 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: ![]() ![]() ![]() |
Molecular weight | Theoretical: 12.072557 KDa |
Recombinant expression | Organism: ![]() ![]() |
Sequence | String: DIVLTQSPTS LAVSLGQRAT ISCRASESVD NFGISFMNWF QQKPGQPPKL LIYAASNLGS GVPARFSGSG SGTDFSLNIH PMEDDDTAM YFCQQSKEVP LTFGAGTKLE LKR |
-Macromolecule #3: Envelope glycoprotein B
Macromolecule | Name: Envelope glycoprotein B / type: protein_or_peptide / ID: 3 / Number of copies: 3 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: ![]() ![]() ![]() |
Molecular weight | Theoretical: 71.668188 KDa |
Recombinant expression | Organism: ![]() ![]() |
Sequence | String: DIKAENTDAN FYVCPPPTGA TVVQFEQPRR CPTRPEGQNY TEGIAVVFKE NIAPYKFKAT MYYKDVTVSQ VWFGHRYSQF MGIFEDRAP VPFEEVIDKI NAKGVCRSTA KYVRNNLETT AFHRDDHETD MELKPANAAT RTSRGWHTTD LKYNPSRVEA F HRYGTTVN ...String: DIKAENTDAN FYVCPPPTGA TVVQFEQPRR CPTRPEGQNY TEGIAVVFKE NIAPYKFKAT MYYKDVTVSQ VWFGHRYSQF MGIFEDRAP VPFEEVIDKI NAKGVCRSTA KYVRNNLETT AFHRDDHETD MELKPANAAT RTSRGWHTTD LKYNPSRVEA F HRYGTTVN CIVEEVDARS VYPYDEFVLA TGDFVYMSPF YGYREGSHTE HTTYAADRFK QVDGFYARDL TTKARATAPT TR NLLTTPK FTVAWDWVPK RPSVCTMTKW QEVDEMLRSE YGGSFRFSSD AISTTFTTNL TEYPLSRVDL GDCIGKDARD AMD RIFARR YNATHIKVGQ PQYYQANGGF LIAYQPLLSN TLAELYVREH LREQSRKPPN PTPPPPGASA NASVERIKTT SSIE FARLQ FTYNHIQRHV NDMLGRVAIA WCELQNHELT LWNEARKLNP NAIASVTVGR RVSARMLGDV MAVSTCVPVA ADNVI VQNS MRISSRPGAC YSRPLVSFRY EDQGPLVEGQ LGENNELRLT RDAIEPCTVG HRRYFTFGGG YVYFEEYAYS HQLSRA DIT TVSTFIDLNI TMLEDHEFVP LEVYTRHEIK DSGLLDYTEV QRRNQLHDLR FADIDTVIHA DANAA |
-Experimental details
-Structure determination
Method | ![]() |
---|---|
![]() | ![]() |
Aggregation state | particle |
-
Sample preparation
Buffer | pH: 7.5 |
---|---|
Vitrification | Cryogen name: ETHANE |
-
Electron microscopy
Microscope | FEI TITAN KRIOS |
---|---|
Electron beam | Acceleration voltage: 300 kV / Electron source: ![]() |
Electron optics | Illumination mode: FLOOD BEAM / Imaging mode: BRIGHT FIELD![]() |
Image recording | Film or detector model: GATAN K3 BIOQUANTUM (6k x 4k) / Average electron dose: 55.8 e/Å2 |
Experimental equipment | ![]() Model: Titan Krios / Image courtesy: FEI Company |